Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Multiple Sclerosis and Rare Diseases of the CNS

No studies found 0 · 0%GRADE not reported 2 · 40%Very low 0 · 0%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

International Index of Erectile Function questionnaire 31 · patients with erectile dysfunction in patients with multiple sclerosis

1 finding from 1 review

Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 420 participants
GRADE not reported

International Index of Erectile Function ‐ not reported · patients with erectile dysfunction in patients with multiple sclerosis

1 finding from 1 review

Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 420 participants
GRADE not reported

Sexual Encounter Profile questions 2 · patients with erectile dysfunction in patients with multiple sclerosis

Sildenafil showed no clear difference in sexual Encounter Profile questions 2 compared with placebo (low certainty).

1 finding from 1 review

Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis 2012 · Cochrane Headline outcomes only
RR 1.28 [0.92, 1.78]
1 study · 184 participants
Low

Sexual Encounter Profile questions 3 · patients with erectile dysfunction in patients with multiple sclerosis

Sildenafil showed no clear difference in sexual Encounter Profile questions 3 compared with placebo (low certainty).

1 finding from 1 review

Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis 2012 · Cochrane Headline outcomes only
RR 1.38 [1, 1.9]
1 study · 187 participants
Low

Global Assessment Question · patients with erectile dysfunction in patients with multiple sclerosis

Sildenafil probably leads to higher global Assessment Question compared with placebo (moderate certainty).

1 finding from 1 review

Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis 2012 · Cochrane Headline outcomes only
RR 2.72 [1.4, 5.28]
2 studies · 406 participants
Moderate